ACAD
26.02
-0.25
-0.95%
AEMD
1.874
+0.064
+3.5193%
APRI
0.95
-0.01
-1.04%
ARNA
1.31
-0.05
-3.68%
ATEC
1.99
-0.04
-1.97%
CNAT
5.17
-0.09
-1.71%
CRXM
0.161
-0.009
-5.4118%
CYTX
1.03
0.00
0.00%
DXCM
68.65
-0.5
-0.72%
GNMK
13.14
+0.14
+1.08%
HALO
12.41
-0.19
-1.51%
ILMN
175.91
+2.15
+1.24%
INNV
0.133
+0.015
+12.807%
INO
7.88
-0.11
-1.38%
ISCO
1.32
-0.17
-11.41%
ISIS
57.56
0.00
0.00%
LGND
110.19
-3.31
-2.92%
LPTN
2.93
-0.08
-2.66%
MBVX
1.66
-0.13
-7.26%
MEIP
2.12
+0.15
+7.61%
MNOV
5.95
-0.1
-1.65%
MRTX
3.25
-0.05
-1.52%
MSTX
0.131
-0.007
-5.278%
NBIX
46.22
-2.42
-4.99%
NUVA
75.52
-0.26
-0.34%
ONCS
1.06
+0.08
+8.16%
ONVO
2.94
+0.09
+3.16%
OREX
2.97
+0.03
+1.02%
OTIC
12.35
-0.3
-2.37%
QDEL
24.91
-0.01
-0.04%
RCPT
231.96
0.00
0.00%
RGLS
1.375
+0.025
+1.852%
RMD
70.07
+0.02
+0.03%
SCIE
0.001
+0.00
+16.6667%
SPHS
2.46
-0.01
-0.40%
SRNE
1.75
+0.1
+6.06%
TROV
0.651
-0.039
-5.6377%
VICL
2.36
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
12.65
-0.25
-1.94%
ACAD
26.02
-0.25
-0.95%
AEMD
1.874
+0.064
+3.5193%
APRI
0.95
-0.01
-1.04%
ARNA
1.31
-0.05
-3.68%
ATEC
1.99
-0.04
-1.97%
CNAT
5.17
-0.09
-1.71%
CRXM
0.161
-0.009
-5.4118%
CYTX
1.03
0.00
0.00%
DXCM
68.65
-0.5
-0.72%
GNMK
13.14
+0.14
+1.08%
HALO
12.41
-0.19
-1.51%
ILMN
175.91
+2.15
+1.24%
INNV
0.133
+0.015
+12.807%
INO
7.88
-0.11
-1.38%
ISCO
1.32
-0.17
-11.41%
ISIS
57.56
0.00
0.00%
LGND
110.19
-3.31
-2.92%
LPTN
2.93
-0.08
-2.66%
MBVX
1.66
-0.13
-7.26%
MEIP
2.12
+0.15
+7.61%
MNOV
5.95
-0.1
-1.65%
MRTX
3.25
-0.05
-1.52%
MSTX
0.131
-0.007
-5.278%
NBIX
46.22
-2.42
-4.99%
NUVA
75.52
-0.26
-0.34%
ONCS
1.06
+0.08
+8.16%
ONVO
2.94
+0.09
+3.16%
OREX
2.97
+0.03
+1.02%
OTIC
12.35
-0.3
-2.37%
QDEL
24.91
-0.01
-0.04%
RCPT
231.96
0.00
0.00%
RGLS
1.375
+0.025
+1.852%
RMD
70.07
+0.02
+0.03%
SCIE
0.001
+0.00
+16.6667%
SPHS
2.46
-0.01
-0.40%
SRNE
1.75
+0.1
+6.06%
TROV
0.651
-0.039
-5.6377%
VICL
2.36
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
12.65
-0.25
-1.94%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Bio Roundup: Skinny Cuts, Genomic Approvals, Unfrozen FDA & More

May 26, 2017 – 2:55 am

Team Trump unveiled its 2018 federal spending proposal—the so-called “skinny budget”—with health and science in the crosshairs. The NIH is looking at a 22 percent cut and the FDA 31…

[[Click headline to continue reading.]]

Halozyme Therapeutics To Present At Upcoming Healthcare Conferences

May 25, 2017 – 12:05 pm

SAN DIEGO, May 25, 2017 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting a corporate overview at three upcoming investor conferences.

Laurie Stelzer, senior vice president and chief financial officer will present at the Jefferies 2017 Global Healthcare Conference in New York on June 8 at 1:30 p.m. ET / 10:30 a.m. PT, and at the JMP Securities 2017 Life Sciences Conference in New York on June 20 at 11:00 a.m. ET / 8:00 a.m. PT.

On Tuesday, June 13, Dr. Helen Torley, president and chief executive officer will present at the Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes at 5:00 p.m. ET / 2:00 p.m. PT.

Webcasts for the presentations can be accessed through the “Investors” section of www.halozyme.com, and a recording will be made available for 90 days following each event. To access a live webcast, please visit Halozyme’s website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme’s lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly for its ENHANZE® drug-delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Contacts:
Jim Mazzola
858-704-8122
ir@halozyme.com

Chris Burton
858-704-8352
ir@halozyme.com

 

SOURCE Halozyme Therapeutics, Inc.

Saturnino (Nino) Fanlo Joins Human Longevity, Inc. As Chief Financial Officer

May 25, 2017 – 8:00 am

Financial Industry Leader Brings 30 Years of Experience Leading Public, Private Companies; Raising Billions in Financing Rounds

SAN DIEGO, May 25, 2017 /PRNewswire/ — Human Longevity, Inc. (HLI), the genomics-based, health intelligence company, announced today that Saturnino (Nino) Fanlo will be joining the company as Chief Financial Officer, reporting to CEO Cynthia Collins. Fanlo brings decades of financial services acumen and strategic leadership to the role at HLI and will be instrumental in helping guide the company as it expands and strengthens commercialization and operations.

“Nino’s 30 years of financial services leadership especially his success in the fintech arena make him the ideal CFO for HLI,” said Collins. “Our company is poised for commercial success and I’m eager to have Nino as a key member of the team to ensure we remain laser focused on our goal of creating health intelligence in the healthcare market.”

“Joining Cindy, Craig Venter and the rest of the strong management team at HLI is a genuine honor. The technologies and products that HLI has created to positively impact the healthcare landscape are remarkable and the chance to contribute my skills and experience to this company is an exhilarating challenge,” said Fanlo.

Fanlo joins HLI from Social Finance, Inc. (Sofi), the largest and fastest growing online lender, where he served as President and Chief Financial Officer. Fanlo was a key leader at Sofi who worked hand in hand with the CEO and founder to design and build capital markets, loan sale, finance, and credit and loan operations there. He led five successful capital raises for more than $1.9 billion and moved the company from an $8 million to a $4.3 billion valuation in under five years. He was also a key architect of many of Sofi’s unique financial products.

Prior to Sofi Fanlo held a series of high level leadership roles in well-respected financial services firms. Before Sofi, he was a Senior Advisor at Golden Gate Capital where he helped to develop their $1 billion Credit Opportunity Fund and the $200 million Public Equity Fund. For 5 years, he served as the CEO of KKR Financial and CIO and Partner of KKR Asset Management where was responsible for capital raising, investment policy, portfolio selection and management, recruiting and development, and investor communications. He led the initial public offering of KKR Financial after just nine months of establishing this spinout. He also raised $4 billion in equity capital and $10 billion of permanent investment capital. 

Prior to that he also served as Executive Vice President and Treasurer of Wells Fargo & Co., where he was responsible for funding, capital and investment portfolio including cash management and liquidity operations. Other roles in his career include leadership positions with Goldman, Sachs & Co., Australian Capital Equity, and First Boston Corporation.

Fanlo received his Bachelor of Economics from Haverford College, Haverford, PA.

About Human Longevity, Inc™
Human Longevity, Inc. (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. HLI’s business areas include the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com.

 

SOURCE Human Longevity, Inc.

Amid Budget Concerns, NIH Preps Beta Test for Precision Medicine Plan

May 25, 2017 – 4:46 am

An ambitious plan to recruit 1 million U.S. volunteers and amass a treasure trove of their health information will start next week with a “beta test” that health officials hope to eventually expand…

[[Click headline to continue reading.]]

Phoenix Molecular Designs Announces New Preclinical Data for Targeted Triple Negative Breast Cancer (TNBC) Therapy

May 25, 2017 – 4:00 am

PMD-026 demonstrates 70% inhibition of ribosomal S6 kinase (RSK) signaling, blocking TNBC tumor growth in mice

VANCOUVER, British Columbia and SAN DIEGO, May 25, 2017 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing precise cancer therapeutics by targeting essential kinases, announced today that it has made a significant research breakthrough in the development of a novel therapy for the treatment of triple negative breast cancer (TNBC) with new preclinical data for its lead asset, PMD-026, an oral small molecule that selectively targets RSK (p90 ribosomal S6 kinase) in TNBC and suppresses tumor growth.

In preclinical studies using the MDA-MB-231 TNBC model, PMD-026 was administered orally over a 28 day time course and demonstrated 70% inhibition of RSK signaling, blocking the growth of TNBC, and importantly, no adverse effects were observed. Within 30 min, PMD-026 was rapidly taken up by tumors whereby it shuts down the central signaling network needed for TNBC to grow. The preclinical model selected is resistant to a wide range of targeted therapies in which tumors do not respond to EGFR or mTOR inhibitors.  In addition, a head to head comparison of PMD-026 versus standard of care (doxorubicin) in the same mouse model showed equal inhibition of tumor growth – and most importantly – PMD-026 demonstrated a more favorable safety profile than doxorubicin.

“The need for new targeted therapies to help patients suffering with TNBC is urgent, but unfortunately novel treatments are extremely scarce.  We are addressing this unmet medical need through a novel, targeted approach by inhibiting critical kinases, such as RSK, known to be involved in the progression of numerous cancer indications,” said Sandra Dunn, Ph.D., Chief Executive Officer of PhoenixMD.  “Our recent favorable preclinical data on PMD-026, coupled with our robust intellectual property estate and leading research collaborations, give us greater confidence in our novel approach to treating cancer.  We look forward to building upon these preclinical results and initiating first-in-man studies with PMD-026 in 2018.”

“Disruptive therapies require thinking outside the box. PhoenixMD has taken a differentiated approach to developing inhibitors for TNBC by relying on functional screens to guide the selection of the fundamental kinase that drives the disease.  In the case of TNBC, RSK appears to be an essential kinase.  RSK inhibitors are new to the kinase scene and PMD-026 is headed for a first-in-class designation,” said Alan Lewis, Ph.D., Chair of the Scientific Advisory Board at PhoenixMD and CEO of Diavacs.  “The therapies being developed at PhoenixMD are designed to treat the most difficult cancer indications.  They are also promising for strategic combinations with check point inhibitors and/or standard of care therapies.  I look forward to working with the established team at PhoenixMD to advance PMD-026 into the clinic.”

Dr. Lewis has led biotech companies focused on developing kinase inhibitors including Signal, Celgene, and Ambit.  Further, he serves on the Board of numerous companies involved with the development of kinase inhibitors including BioMarin.

About Triple Negative Breast Cancer (TNBC) and RSK Kinases

Approximately 170,000 cases of TNBC are diagnosed every year worldwide and it is one of the most difficult breast cancer subtypes to treat due to lack of effective, targeted therapies.  TNBC also claims the lives of young women more than any other type of breast cancer due to a lack of understanding around the therapeutic bullseye.  It is also a very heterogeneous disease, therefore a common denominator across TNBC types was necessary to identify the bullseye.  Through genome-wide screens, RSK was identified as the prime target for TNBC by scientists at PhoenixMD. Currently, there are still no targeted therapies available for TNBC.

There are four types of RSK involved in cancer, known as RSK1-4, and each type has a unique role in the development of the disease. RSK1 is responsible for cancer cell invasion and is an important driver in the spread of cancer. RSK2 controls cancer cell growth, while RSK3 and RSK4 are associated with drug resistance.

RSK1 and RSK2 have been proven critical to the survival of patients with TNBC.  Over 90% of primary TNBC express high levels of RSK1 and RSK2.  Inhibiting RSK2 eliminates TNBC cells completely, including cancer stem cells, which give rise to cancer recurrence.  PhoenixMD, with its novel, targeted approach, is focused on creating patented cancer RSK inhibitors and companion diagnostics for cancer indications – initially in breast cancer – with the potential to treat blood, brain, ovarian, lung, skin, prostate, colon, head and neck cancers.

About PhoenixMD

PhoenixMD is a privately-held biopharmaceutical company designing precise cancer therapeutics and companion diagnostics by targeting kinases, a class of highly druggable enzymes to treat a wide range of oncology indications.  PhoenixMD is focused on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation.  Due to its emerging leadership in kinase inhibition, PhoenixMD has entered into partnerships with well-recognized academic and non-profit institutions such as the National Cancer Institute (NIH), University of Florida, Kyushu University, Mayo Clinic, and University of Hawaii Comprehensive Cancer Center. PhoenixMD is headquartered in Vancouver, British Columbia Canada with U.S. operations in San Diego, CA.  For more information, visit phoenixmd.ca.

Media Contact:
Amy Conrad
Juniper Point
Ph: (858) 366-3243
amy@juniper-point.com

SOURCE Phoenix Molecular Designs

Phase 1 Safety Study Supports Planned Development of PCM-075 in AML

May 25, 2017 – 4:00 am

Study evaluated safety, dose limiting toxicities, related maximum tolerated dose and indication of anti-tumor activity in patients with advanced or metastatic solid tumors

SAN DIEGO, May 25, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced summary data from a phase 1 safety study conducted by Nerviano Medical Sciences with PCM-075, a polo-like kinase 1 (PLK1) inhibitor.  This data is supportive of a planned phase 1/2 clinical trial in patients with acute myeloid leukemia (AML) and is now being submitted for peer review publication by study investigators.

The phase 1 safety study was an open-label, dose-escalation trial in patients with advanced or metastatic solid tumors.  PCM-075 was administered orally, once daily for five consecutive days, every day for three weeks, to evaluate drug metabolism and first cycle dose-limiting toxicities (DLTs) and related maximum tolerated dose (MTD).  The study also evaluated PCM-075’s pharmacokinetic profile in plasma, its anti-tumor activity, and its ability to modulate intracellular targets in biopsied tissue.

The phase 1 study enrolled 21 patients with confirmed metastatic disease and a mean age of 62.7 years.  These patients received study medication at doses up to 48 mg/m2/day.  The most common cancer types for enrolled patients included colon, pancreatic, lung, and head and neck cancer.

Thrombocytopenia and neutropenia were identified as the primary DLTs, which are consistent with the expected mechanism of action and results from preclinical studies.  These hematologic toxicities were reversible.  One patient experienced grade 3 constipation, which may have been due to concomitant treatment with opiates.  No other clinically relevant safety findings emerged. 

“Hematologic side effects are expected with PLK inhibitors, which induce mitotic cell cycle arrest preferentially in rapidly proliferating blood cells, leading to cell death.  This suggests anti-tumor activity in hematologic malignancies and supports our plans to develop PCM-075 for the treatment of AML,” said Dr. Mark Erlander, Chief Scientific Officer of Trovagene. “We believe the phase 1 data indicates broad applications for PCM-075 in hematologic malignancies and solid tumors and we plan to continue to assess, and explore, additional precision cancer therapeutic opportunities going forward.”

The complete phase 1 data, study details and conclusions are part of the manuscript that will be submitted by study investigators for peer review publication. 

About Trovagene, Inc.
Trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics.  Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies.  Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics.  For more information, please visit www.trovagene.com.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Trovagene’s expectations, strategy, plans or intentions. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially.  There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.  These factors include, but are not limited to, our need for additional financing; our ability to continue as a going concern; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; our ability to develop tests, kits and systems and the success of those products; regulatory, financial and business risks related to our international expansion and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.  There are no guarantees that any of our technology or products will be utilized or prove to be commercially successful, or that Trovagene’s strategy to design its liquid biopsy tests to report on clinically actionable cancer genes will ultimately be successful or result in better reimbursement outcomes.  Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful.  Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2016, and other periodic reports filed with the Securities and Exchange Commission.  While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties.  Unlisted factors may present significant additional obstacles to the realization of forward-looking statements.  Forward-looking statements included herein are made as of the date hereof, and Trovagene does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Trovagene Contact:
Vicki Kelemen
Sr. Director, Corporate Communications
858-952-7652
vkelemen@trovagene.com

SOURCE Trovagene, Inc.

Invitae Broadens Management Team to Scale Expanding Business and Meet Rising Demand

May 25, 2017 – 3:30 am

— Shelly Guyer appointed chief financial officer as Lee Bendekgey takes on role of chief operating officer —

SAN FRANCISCO, May 25, 2017 /PRNewswire/ — Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, announced that industry veteran Shelly Guyer, most recently chief financial officer at Veracyte, Inc., a genomic diagnostics company, has been named chief financial officer, effective June 12, 2017. Upon her appointment, Invitae’s current chief financial officer, Lee Bendekgey, will fully transition to the role of chief operating officer.

“I’m thrilled to be joining Invitae’s team of thought leaders to help position the company as an innovator in the dynamic and ever-changing genomics market,” said Shelly Guyer, future chief financial officer of Invitae. “It is an exciting time to be joining Invitae as the company continues to redefine the genetic information field and begins to evolve its business beyond the traditional scope of diagnostic testing to include industry-leading content, support, and services.”

Ms. Guyer has extensive experience building and leading strong financial functions as a senior executive and leader in life sciences, as well as domain expertise from years as an investment banker and venture capitalist. Prior to her CFO position at Veracyte, Ms. Guyer served as CFO and EVP of finance and administration at iRhythm Technologies, Inc., a digital healthcare company redefining the clinical diagnosis of cardiac arrhythmias. She began her business career at Hambrecht & Quist and later J.P. Morgan Securities, where for more than 17 years she held various positions, including principal of healthcare banking for the West Coast, leading financings for a variety of large and small cap life science companies. Ms. Guyer holds an AB from Princeton University and an MBA from the Haas School of Business, University of California, Berkeley.

“Broadening our management team to include the depth of experience Shelly brings will help ensure Invitae has the operational and financial infrastructure to support our long-term vision of ensuring comprehensive, affordable access to the highest quality genetic information,” said Lee Bendekgey, future chief operating officer of Invitae. “In my new role, I will be focused on ensuring that as we expand our platform to broaden the utility of genetic information, we do so in a cost-effective, scalable manner that meets current demand and future opportunity.”

About Invitae

Invitae Corporation’s (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic service comprising approximately 1,500 genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas, as well as a clinical whole exome analysis service. Additionally, the company has created a Genome Network to connect patients, clinicians, advocacy organizations, researchers, and therapeutic developers to accelerate the understanding, diagnosis, and treatment of hereditary disease. For more information, visit our website at invitae.com.

Safe Harbor Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s new management appointments and its future growth and position in the market; the company’s rapid rise to the top of the genetic information field and the beginning of its evolution from traditional diagnostic testing to industry-leading content, support and services; the company’s commitment to continue delivering high quality genetic tests and drive continued growth in its Genome Network; and that broadening the company’s management team will help ensure it has the operational and financial infrastructure to support its near-term growth and long-term goals. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to:  risks associated with the loss of any member of the company’s senior management team; the company’s ability to manage growth effectively, the company’s ability to use rapidly changing genetic data to interpret test results accurately and consistently; the company’s history of losses; the company’s ability to compete; laws and regulations applicable to the company’s business; and the other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2016. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

NOTE: Invitae and the Invitae logo are trademarks of Invitae Corporation. All other trademarks and service marks are the property of their respective owners.

Source: Invitae Corporation

Investor Contact:
Kate McNeil
ir@invitae.com
347-204-4226

Media Contact:
Laura D’Angelo
pr@invitae.com
314-920-0617

SOURCE Invitae Corporation

Halozyme Therapeutics Announces Completion Of Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares

May 24, 2017 – 12:05 pm

SAN DIEGO, May 24, 2017 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the completion of its previously announced underwritten public offering of 11,500,000 shares of its common stock. The offering included 1,500,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. All shares in the offering were sold by Halozyme at a public offering price of $12.50 per share. Net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, were approximately $135 million.

Halozyme intends to use the net proceeds from this offering to fund continued development of its PEGPH20 oncology program and for other general corporate purposes.

Wells Fargo Securities, LLC and Deutsche Bank Securities acted as joint book-running managers for the offering. Barclays and JMP Securities acted as co-managers for the offering.

An automatic shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the “SEC”) and is effective. A final prospectus supplement and accompanying prospectus relating to this offering have been filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus may be obtained from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by telephone at (800) 326-5897 or email to cmclientsupport@wellsfargo.com; or Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005, or by telephone at (800) 503-4611 or email to prospectus.cpdg@db.com. Electronic copies of the final prospectus supplement and accompanying prospectus are also available on the website of the SEC at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment.

Safe Harbor Statement
All of the statements in this press release that are not statements of historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such statements include Halozyme’s intended use of proceeds. These statements are based upon management’s current plans and expectations and are subject to a number of risks and uncertainties which could cause actual results to differ materially from such statements. A discussion of the risks and uncertainties that can affect these statements is set forth in Halozyme’s prospectus supplement and the accompanying prospectus filed with the SEC on May 19, 2017, together with the information incorporated by reference, under the heading “Risk Factors.”  Halozyme disclaims any intention or obligation to revise or update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:
Jim Mazzola
858-704-8122
ir@halozyme.com

Chris Burton
858-704-8352
ir@halozyme.com

 

 

SOURCE Halozyme Therapeutics, Inc.

Kindred Biosciences to Present at 7th Annual LD Micro Invitational

May 24, 2017 – 5:01 am

SAN FRANCISCO, May 24, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and COO, will be presenting and hosting one-on-one investor meetings at the 7th Annual LD Micro Invitational in Los Angeles, CA on Tuesday, June 6, 2017 at 1:30 PM PST. The conference will be held at the Luxe Sunset Bel Air Hotel.

Following the presentation, the slide deck will be available for 30 days on the Company’s website: http://kindredbio.com/investor-relations/events.

About Kindred Biosciences, Inc. 

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses.  The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Contact

Russell Radefeld
KindredBio
Russell.radefeld@kindredbio.com 
(650) 701-7904

 

SOURCE Kindred Biosciences, Inc.

Forge Therapeutics To Present New Data On Novel Gram-Negative Antibiotic Program At ASM Microbe 2017

May 24, 2017 – 4:00 am

SAN DIEGO, May 24, 2017 /PRNewswire/ — Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, announced today that the company will present new preclinical data on its novel antibiotic program in an oral talk and poster presentation at ASM Microbe 2017 being held June 1-5, 2017 in New Orleans.

Oral Talk: Saturday, June 3, 2017, 1:25 – 1:35 p.m. EDT

Poster Presentation: Sunday, June 4, 2017, 12:15 – 2:15 p.m. EDT

About LpxC and the ‘Superbug’ Epidemic

Millions of people around the globe have become infected with bacteria that are resisted to current antibiotic treatments, or ‘superbugs’, creating a global health epidemic. An estimated 700,000 worldwide deaths occur each year from these drug-resistant infections, and in the U.S. alone, an estimated 23,000 people die each year from antibiotic resistant infections.  The biotechnology industry, leading government agencies and world leaders agree that the need for new antibiotics is urgent.

LpxC, is an attractive and highly sought after antibiotic target – it is conserved across Gram-negative bacteria and not found in Gram-positive bacteria or human cells.  Other LpxC inhibitors have been evaluated by biopharma in the past but chemistry limitations (e.g. hydroxamic acid) have yielded ineffective compounds that suffer from poor drug-like properties.  Thus, there are no approved therapeutics targeting LpxC.  Forge, using its proprietary chemistry platform, has developed novel non-hydroxamate inhibitors of LpxC that are safe and effective in an animal model of Gram-negative infection and are able to kill Gram-negative ‘superbugs’ where other antibiotics are ineffective.

About Forge Therapeutics

Forge Therapeutics is a privately-held biopharmaceutical company developing novel antibiotics to treat multi-drug resistant bacteria, or ‘superbugs,’ that have ignited a global health epidemic.  With its proprietary chemistry approach, Forge develops small molecule inhibitors targeting metalloenzymes.  Forge’s lead effort is focused on LpxC, a zinc metalloenzyme found only in Gram-negative bacteria and which is essential for bacteria to grow.  Forge has discovered novel small molecule inhibitors of LpxC that are potent in vitro, efficacious in vivo, and effective against drug resistant Gram-negative bacteria ‘superbugs.’  To complement its innovative approach to drug discovery, Forge has a capital efficient business model that utilizes a mix of non-dilutive and traditional funding sources to advance its programs, including LpxC.  Forge has formed a strategic alliance with leading drug discovery alliance and development partnership company Evotec AG and has been awarded multiple government awards to address the global ‘superbug’ epidemic.  In addition, Forge has amassed a rich intellectual property estate on metalloprotein inhibitors to protect its technology and pipeline.  For further information, please visit the company’s website www.ForgeTherapeutics.com and follow us on Twitter @ForgeThera.

Forge Company Contact:
Info@ForgeTherapeutics.com

Forge Media Contact:
Amy Conrad
Juniper Point
amy@juniper-point.com
858-366-3243

SOURCE Forge Therapeutics, Inc.